Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Queensland Health
Fish and Richardson
Baxter
Fuji
McKinsey
Medtronic
McKesson
QuintilesIMS
UBS

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022100

« Back to Dashboard

NDA 022100 describes AZOR, which is a drug marketed by Daiichi Sankyo and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the AZOR profile page.

The generic ingredient in AZOR is amlodipine besylate; olmesartan medoxomil. There are fifty drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the amlodipine besylate; olmesartan medoxomil profile page.
Summary for 022100
Tradename:AZOR
Applicant:Daiichi Sankyo
Ingredient:amlodipine besylate; olmesartan medoxomil
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 022100
Suppliers and Packaging for NDA: 022100
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AZOR amlodipine besylate; olmesartan medoxomil TABLET;ORAL 022100 NDA Physicians Total Care, Inc. 54868-6036 54868-6036-0 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (54868-6036-0)
AZOR amlodipine besylate; olmesartan medoxomil TABLET;ORAL 022100 NDA Physicians Total Care, Inc. 54868-6250 54868-6250-0 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (54868-6250-0)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE;20MG
Approval Date:Sep 26, 2007TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Oct 25, 2016Product Flag?Substance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE;40MG
Approval Date:Sep 26, 2007TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Oct 25, 2016Product Flag?Substance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE;20MG
Approval Date:Sep 26, 2007TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Oct 25, 2016Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 022100

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo AZOR amlodipine besylate; olmesartan medoxomil TABLET;ORAL 022100-001 Sep 26, 2007 ➤ Subscribe ➤ Subscribe
Daiichi Sankyo AZOR amlodipine besylate; olmesartan medoxomil TABLET;ORAL 022100-002 Sep 26, 2007 ➤ Subscribe ➤ Subscribe
Daiichi Sankyo AZOR amlodipine besylate; olmesartan medoxomil TABLET;ORAL 022100-003 Sep 26, 2007 ➤ Subscribe ➤ Subscribe
Daiichi Sankyo AZOR amlodipine besylate; olmesartan medoxomil TABLET;ORAL 022100-004 Sep 26, 2007 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Fish and Richardson
Colorcon
Moodys
UBS
Johnson and Johnson
Healthtrust
Farmers Insurance
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot